ForteBio Launches Dip and Read™ Anti-Human Fab-CH1 Biosensor to Accelerate Human Biotherapeutic Drug Development

  ForteBio Launches Dip and Read™ Anti-Human Fab-CH1 Biosensor to Accelerate
  Human Biotherapeutic Drug Development

Business Wire

PORT WASHINGTON, N.Y. -- January 9, 2013

ForteBio, a division of Pall Life Sciences and a leading supplier of
label-free technology that accelerates the development of biotherapeutic and
pharmaceutical products, today announced the launch of its Dip and Read
Anti-Human Fab-CH1 biosensor. The new biosensor enables an easy and rapid
method for quantitation and kinetic characterization of human Fab, F(ab’)2 and
IgG – critical processes in drug discovery. Dip and Read biosensors are
designed for use on ForteBio’s Octet® and BLItz™ instrumentation systems.

“The detection and characterization of human IgG is of paramount importance to
research scientists,” said Christopher Silva, the ForteBio division’s vice
president of marketing. “However, traditional approaches to quantitation and
kinetic characterization have been cumbersome, slow and expensive. Our new
Anti-Human Fab-CH1 biosensor carries the popular CaptureSelect® IgG-CH1 ligand
from BAC BV, a company that provides affinity tools widely used in
purification of antibodies and antibody fragments. The new biosensor offers
researchers unparalleled ease of use and time-to-result in a wide range of
laboratory applications, enabling improved laboratory workflow and

The Anti-Human Fab-CH1 biosensor consists of a pre-immobilized high-affinity,
anti-human CH1 affinity ligand that binds specifically to the CH1 domain of
all four human IgG subclasses independent of the type of light chain. Its
unique selectivity provides solid coverage of any human IgG derived Fab
fragment without interference of notorious product-related contaminants like
over-expressed free light chains. The high specificity of the biosensor
enables direct analysis of human Fab/F(ab’)2/IgG in crude lysates, column
eluants, cell lysates and cell culture supernatants, providing a time-saving
alternative to traditional analytical methods.

The Octet family of products is based on ForteBio’s proprietary Bio-Layer
Interferometry (BLI) technology. It incorporates disposable optical Dip and
Read biosensors that measure multiple interactions in parallel, without the
use of detection agents. For single-sample analysis, ForteBio recently
launched its BLItz platform. The new platform revolutionizes the use of
label-free protein analysis by making it more accessible and cost-effective
for individual bench scientists in biotherapeutic discovery, process
development and academic research.

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical
systems to accelerate biotherapeutic drug discovery and development. These
systems enable real-time, label-free analysis of biomolecular interactions,
providing information on affinity, kinetics and concentration. ForteBio’s
analytical capabilities enable significantly easier, faster and better
characterization of drug candidates, thus providing greater value in drug
development applications where existing methods have limitations in
throughput, performance and cost. For more information, visit

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides
cutting-edge products and services to meet the demanding needs of customers
discovering, developing and producing biotech drugs, vaccines and classic
pharmaceuticals. Its membranes and membrane devices optimize detection and
sample preparation in the drug research, clinical diagnostics, genomics, and
proteomics markets. Pall Life Sciences is a leading provider of separation
systems and single-use filtration and purification technologies to
pharmaceutical and biotechnology companies to support faster development of
new drugs and vaccines that are safer and require less energy and water to
produce. Pall Life Sciences’ technologies are also used in clinical
institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification
leader providing solutions to meet the critical fluid management needs of
customers across the broad spectrum of life sciences and industry. Pall works
with customers to advance health, safety and environmentally responsible
technologies. The company’s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a “top green company”
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit

Photos/Multimedia Gallery Available:



Doug Novarro
Pall Corporation
Corporate Public Relations
Follow us on Twitter @pallcorporation
Gemma Milan
Press spacebar to pause and continue. Press esc to stop.